Page 3 - Phasei Ii News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ObvioHealth announces upgraded decentralized trial platform The company’s technology facilitates remote patient monitoring and integrates with a wide range of wearable sensors for checking patient vital signs. ObvioHealth has introduced a new platform that enables advanced remote-patient monitoring capabilities for decentralized trial solutions. The company’s decentralized platform and patient-centric smartphone app are designed to help create an ‘ecosystem’ of technology and devices approved by the US Food and Drug Administration (FDA) to support remote mo...

Introduction to eLAS® Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS ®​) to address fundamental challenges impacting systemic lupus erythematosus (SLE) studies and the integrity of the study endpoints. eLAS is a therapeutic-specific application of Clinical Ink’s Lunexis™. Unlike other applications that simply offer stand-alone electronic versions of questionnaires, eLAS features a fully integrated suite of SLE disease assessment questionnaires, physical assessment, tender/swollen joint count, PGA, and summary forms. Latest content from Cl...

Real-Time, Integrated Data Capture With Unprecedented Freedom of Choice

A leader from Vocalis Health explains how health data can be culled from patient voice recordings to screen and monitor COVID-19 and other conditions. OSP: Could you please share the ‘elevator presentation’ description of Vocalis—who you are, what you do, and what sets you apart?​ SH: Vocalis Health is an AI health tech company pioneering the development of vocal biomarkers – where health-related information is derived from analysis of people’s voice recordings – to screen, detect, monitor and predict health symptoms, conditions and diseases.  In 201...

According to Noxopharm, a recent study shows combining its Veyonda drug and a radiopharmaceutical yields favorable results against prostate cancer. Noxopharm has released the most recent survival data from its LuPIN prostate cancer study. The company reports results show a median overall survival (mOS) of 19.7 months, higher than all other mOS results for existing prostate cancer treatments in their own registration studies. These findings reportedly support evidence that a combination of Veyonda (NOX66) and experimental radiopharmaceutical 177lutetium-PSMA-617 cou...